Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 18%
Buy 24%
Hold 47%
Sell 6%
Strong Sell 6%

Bulls say

Zimmer Biomet Holdings is well-positioned in the orthopedic market, with a leading share in the US, Europe, and Japan. The company's recent acquisitions have strengthened its product portfolio, particularly in large joints and extremities. Although the first quarter of 2026 had some issues, the company's strategic initiatives and product launches are expected to contribute positively to its longer-term fundamentals. While not without risks, optimistic analysts believe that Zimmer Biomet has the potential for faster revenue and earnings growth, which could lead to a higher valuation for the company.

Bears say

Zimmer Biomet Holdings is facing challenges with its sales force transformation, causing disruptions in the market and contributing to underperformance in the US knees segment. This transition is expected to continue until 2027 and may lead to short-term executional hurdles. Although the company has a strong market share and a diverse product portfolio, these factors may outweigh its long-term potential for financial returns and multiple expansion, leading to a negative outlook on the stock.

ZBH has been analyzed by 17 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 24% recommend Buy, 47% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 17 analysts, ZBH has a Hold consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.